Cell free protein synthesis has become a powerful method for the high-throughput production of proteins that are difficult to express in living cells. The protein SAP2 of Fasciola hepatica (FhSAP2), which has demonstrated to be both, an excellent vaccine candidate against experimental fascioliasis and a good antigen for serodiagnosis of human chronic fascioliasis, is a typical example of a molecule that is difficult to produce. This is mainly due to its tendency to get over-expressed in inclusion bodies by prokaryotes. FhSAP2 expressed in an Escherichia coli-based expression system is poorly glycosylated, insoluble and often undergoes improper folding leading it to reduced immunogenicity. In this work, FhSAP2 was expressed in vitro using the eukaryote cell free system, TNT T7 Quick coupled transcription/translation, that has been designed for the expression of PCR-generated DNA templates. FhSAP2 was expressed in micro-volumes and purified by an affinity chromatography method, which gave a protein yield of 500 µg/ml as determined by bicinchoninic acid assay method. Circular dichroism, Western blotting and enzyme-linked immunosorbent assay analysis were used to confirm the secondary structure, purity and integrity of protein. Results demonstrate that FhSAP2 can be expressed in a cell-free system retaining its main conformational and antigenic properties. The protein purified could be used in immunization experiments and immunodiagnostic techniques.
Introduction
Over the last half century there has been a continuous interest in the development of cell-free expression systems based on eukaryotic organisms, which have been attributed a wide spectrum of applications that range from bioengineering [1] , identification of novel drugs [2] , nano-biotechnology [3] , evolutionary biology [4] and high-throughput proteomics [5] . Compared to the cell-based expression systems, cell free expression systems offer great advantages, such as a shorter production process and the possibility to express multiple proteins simultaneously using PCR products without the tedious, complex and laborious cloning and transformation steps [6] . Moreover, eukaryotic cell free expression systems have the additional advantage of providing post-translational modifications, such as glycosylations; an option that is not possible in any prokaryotic expression system [7] . In the current study, we explored the use of cell-free synthesis for the rapid expression of an antigenic protein belonging to the saposin-like protein family of Fasciola hepatica (FhSAP2), which is the parasite responsible for acute and chronic fascioliasis disease. Although not as deadly as malaria or 1 3 schistosmiasis, fascioliasis is a disease that substantially burdens the human population in two main endemic hubs: Peru and Bolivian Altiplano [8] . Moreover, according to the world health organization, not only there are about 180 million persons at risk of infection worldwide, but fascioliasis is also responsible for more than US$2 billion in economic losses per year worldwide [9] .
FhSAP2 was primarily identified by immuno-screening an adult fluke cDNA library, and was further cloned in an Escherichia coli expression vector and characterized immunologically and biochemically [10] . FhSAP2 has shown to be a highly specific antigen capable of detecting both, acute and chronic infection in experimental animals [10, 11] , as well as chronic human fascioliasis cases using enzymelinked immunosorbent assay (ELISA) or Luminex assays [4, 12] . Additionally, FhSAP2 has shown to be an excellent immunogen capable of inducing partial protective immune responses in mice and rabbits challenged with F. hepatica [11, 13] . As do all members of the saposin-like protein family (SAPLIP) family, FhSAP2 possesses in its protein moiety 6-conserved cysteines and seven hydrophobic residues arranged within five amphipathic α-helical domains at positions that are strictly conserved [10] . FhSAP2 also possesses lineal and conformational B-cell epitopes throughout its whole molecule [14] . Therefore, the antigenicity of this molecule greatly depends on the disulfide bond formations and proper folding, which are both very difficult to achieve because FhSAP2 is usually expressed as insoluble inclusion bodies in E. coli. Although several strategies to solubilize inclusion bodies and achieve the protein refolding have been successfully assayed [10, 15, 16] , the whole process to express and purify FhSAP2 is tedious, time-consuming and often inefficient when relative large protein batches are needed. In the present study, we accomplished the expression of FhSAP2 in vitro using a TNT T7 Quick Coupled Transcription/Translation system. The protein was expressed fused with a His-tag at the carboxyl end and was purified by immobilized metal affinity chromatography (IMAC). Circular dichroism (CD), western blotting and ELISA analysis demonstrated that the purified protein retains its main structural and antigenic properties. Compared to the conventional expression in E. coli, this approach allows a relatively higher protein yield with minimal processing time. It can thus be used for the large-scale production of FhSAP2 for subsequent immunization protocols or immunodiagnostic use.
Materials and methods

Rabbit sera
For this study, we produced two rabbit polyclonal antibodies against recombinant FhSAP2 expressed in bacteria [10] and against F. hepatica excretory-secretory products (ESPs) obtained by in vitro culture of adult flukes for 24-h in RPMImedia [17] . Rabbits were immunized with 250 µg FhSAP2 or ESPs mixed with an equal amount of complete Freund's adjuvant by subcutaneous injection. The rabbits were boosted twice with equal amounts of protein mixed with in-complete Freund's adjuvant at 2-week intervals. Blood was collected 2 weeks after the last immunization and evaluated by ELISA for specific antibody production. Four New Zealand White (NZW) rabbits were infected orally with 60 F. hepatica metacercariae each. Blood was obtained for the collection of serum before infection and then at 4th and 12th weeks after infection. Antisera preparation and animal infections were performed after obtaining the authorization of the Institutional Animal Care and Use Committee of University of Puerto Rico (IACUC # 7870110).
Preparation of enzyme conjugate
Serum IgG was precipitated from the rabbit anti-FhSAP2 serum by adjusting the injection solution to 40% saturation with saturated ammonium sulfate. The precipitated IgG fraction was suspended in a small volume of 0.01 M phosphate buffered saline (PBS), pH7.2, dialyzed against an excess of PBS, and passed through a prepacked protein A-horseradish peroxidase (HRP) 5/5 column (GE Healthcare). IgG was concentrated to 10 mg/ml by using a high-flow membrane filter (YM-100; Amicon Corp.) and conjugated to HRP (type VI; Sigma) using the Nakane and Kawaoi method [18] .
PCR-template preparation
FhSAP2 protein is encoded by 300-bp complementary DNA (cDNA) (GenBank # AF286903), which is cloned in frame into pBAB-His-B expression vector [10] . cDNA-FhSAP2 was used to amplify a PCR product using primers of 50-mers length each specifically designed for this study. The forward primer containing the T7 promoter matches 21-bases of the encoding region of the FhSAP2 gene, including the ATG start codon. A Kozak consensus sequence and two short spacer sequences were also added at the 5′ forward primer to ensure the efficiency of the translation initiation. To enhance the translation of the PCR-product, a Poly (T) 30 tail was added to the 5′-end reverse primer, which matches 21-bases of the carboxyl terminus of the FhSAP2 gene including the stop codon (TAG). Reverse primers also contained a poly-histidine region (6×His) to facilitate the purification of recombinant protein by IMAC (Fig. 1a, b) . PCR was performed using a KOD Extreme Hot Start DNA polymerase (EMD Millipore 71975-3) in a thermocycler Model Veriti (Thermofisher, USA) and 200-pMol primers. The cycling parameters were: 94 °C for 2 min as an initial denaturing step, followed by 98 °C for 10 s, annealing at 58 °C for 30 s, 1 min extension at 68 °C for 30 cycles, and a final extension at 68 °C for 5 min. After, the PCR product was analyzed by 1.5% agarose gel electrophoresis, as expected we obtained a unique band of ~ 390-bp (Fig. 1c) .
Cell-free protein expression
To achieve the synthesis of FhSAP2 in vitro we used the TNT (rabbit reticulocyte lysate) T7 Quick Coupled Transcription/Translation system (Promega Catalog # L1170) designated for expression of PCR-generated DNA templates. Eight micro-tubes containing each the following reaction mixture were prepared: 40 µl TNT T7 Quick Master Mix + 1 µl 1 mM methionine, 5 µl PCR-generated DNA template (829 ng/µl) + 1 µl of TNT T7 PCR enhancer + 3 µl nuclease free water (final volume 50 µl). After a gentle agitation, the tubes were incubated at 30 °C for 90 min. The protein synthesized in each micro-tube was analyzed by 12.5% sodium dodecyl sulfate gel electrophoresis (SDS-PAGE) under no reduction conditions using the Laemmli method [19] . The unstained gel was transferred onto a nitrocellulose membrane and incubated overnight at 4 °C with specific anti-FhSAP2-HRP conjugate diluted 1:2500 revealing the presence of monomeric and oligomeric forms of FhSAP2. Tubes were pooled and loaded onto a 5 ml HisTrap HP column (GE Healthcare, USA). His-tagged protein was eluted by washing the column with 20 mM sodium phosphate containing 0.5 M NaCl + 500 mM imidazole, pH 7.4. Fractions collected were pooled, desalted against PBS using a PD-10 column (Sephadex G-25), and concentrated by an AMICON ultrafiltration system using an YM-3 membrane (> 3 kDa). Purified protein, designated as S-FhSAP2, was analyzed by SDS-PAGE, as described above, in the presence or absence of 2-mercaptoethanol and coomassie blue was used for gel staining. Protein concentration was measured using the bicinchoninic acid assay (BCA) method.
Secondary structure analysis and circular dichroism (CD)
The absorption spectra of S- 
Fig. 1 Primers designed and genetic construct assembly. a, b
Forward primer-containing T7 polymerase promoter, spacer sequences and the Kozak sequence (CCACC) was synthesized. In the reverse primer a tag of 6-histidine and a poly adenine tail sequence for RNA product stability were added. c PCR product amplified with these primers was analyzed by 1.5% agarose gel electrophoresis resulting in a ~ 390-bp product, which include ~ 300-bp FhSAP2 sequence + 39-bp T7 forward + 51-bp T7 reverse CD spectrometer and protein concentrations of 0.1 mg/ml in 50 mM phosphate buffer, pH 8.0 in the 190-250 nm ranges at 20 and 95 °C using 0.1-cm pathlength cell.
Determination of the antigenicity of the cell-free synthesized protein
To determine the antigenicity of S-FhSAP2, the protein was tested against the anti-ESP polyclonal antibody and against sera from rabbits with 4 weeks of F. hepatica infection. For this purpose, an ELISA protocol was developed, which was optimized via checkerboard titration. Antigen, serum, and conjugate were assayed at different concentrations to maximize the sensitivity of the assay. The optimal concentration of S-FhSAP2 was determined to be 2.5 µg/ml, and the optimal dilution of serum and conjugate was determined to be 1:200 and 1:5000, respectively (data not shown). The ELISA was performed following a basic protocol as previously reported [12] .
Statistical analysis
All ELISA determinations were performed in duplicate and the experiment was replicated twice. Absorbance values were expressed as mean absorbance value for each determination. The Student's t test to determine differences between serum samples was performed using Graphpad Prism software (Prism-6). For all tests, a p value of < 0.05 was deemed significant.
Results and discussion
When the micro-reactions containing the FhSAP2-PCR template were incubated at 30 °C for 90 min, the protein obtained from the PCR product demonstrated no variation within the expression tubes in terms of total yield and soluble fractions, which was determined by testing each reaction mix via western blotting against the anti-FhSAP2 antibody-HRP conjugates. As expected, the antibody recognized the typical 12-14 kDa polypeptide of recombinant FhSAP2, which includes 11.5 kDa of the amino sequence plus 2.5 kD corresponding to the His-tag located at the carboxyl terminus of the protein moiety (Fig. 2a) . In addition, the antibody reacted with a polypeptide of ~ 29 kDa that presumably corresponds to the oligomeric forms of FhSAP2, which are formed due to the presence of several intrachain or interchain disulfide bonds [20] . Once we confirmed that all tubes contained FhSAP2, they were pooled and the protein was purified by IMAC using a HisTrap HP 5/5 column (Fig. 2b) and again analyzed by SDS-PAGE in the presence of 2-mercaptoethanol, to achieve disulfide bonds reduction.
Results demonstrated that after 2-mercaptoethanol treatments, the polypeptide band of 29 kDa reduced in intensity (Fig. 3a) , confirming that these oligomers are formed due to the presence of several intrachain or interchain disulfide bonds. Both, monomeric and oligomeric forms of FhSAP2 have been detected using monoclonal antibodies in soluble crude extracts of F. hepatica adult flukes [20] . CD analysis also revealed that the protein synthesized in vitro exhibits a high content of alpha helixes with a maximum and minimum in spectra between 197-201 and 210-225 nm respectively, which is the typical secondary structure all members in the saposin-like protein family exhibit [21] [22] [23] . The maximum (Fig. 3b) . The presence of six alpha helical motif and six cysteine residues at positions strictly conserved is one of the most notable structural characteristic of FhSAP2 [10] . A previously optimized ELISA [11] was used to test the protein's capacity to react with a pool of sera raised against F. hepatica ESPs, a pool of serum from animals with 4 weeks of F. hepatica infection and the anti-FhSAP2 antibody. We had previously demonstrated that FhSAP2 is a component of the F. hepatica ES products [10] , is expressed at early stages of parasite development [20] and is reactive with early sera infection [10, 11] . Therefore, the finding that our cell-free expressed protein is reactive with all these sera (Fig. 3c) indicates that FhSAP2 is not only structurally similar to the native protein, but that it also retained its antigenic properties. According to the relative concentration of FhSAP2 determined by the bicinchoninic acid method [24] , the current cell free expression approach had the ability to produce a batch yield of up to 500 µg/ml active FhSAP2 in 90 min, which is a yield higher than the conventional E. coli expression system obtained after purifying protein in soluble form from inclusion bodies with a significantly lower processing time (Fig. 3d) .
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Conclusions
In summary, we have successfully applied an existing commercial cell-free expression system as an approach to produce recombinant FhSAP2 in vitro. Our results show that this F. hepatica protein can be efficiently expressed with relatively high yields and displayed the same conformational antigenicity without the tedious, and time-consuming process of expression in E. coli. With this approach, the issue of soluble expression was fully addressed. Because the presented methodology could be easily scaled up for production, we consider it a viable option when large batches of protein are required. Based on this study, we conclude . A Jasco J-1500 CD spectrometer was used with protein concentration of 0.1 mg/ml in 50 mM phosphate buffer, pH 8.0 in the 190-250 nm ranges at 25 °C using 0.1-cm path-length cell. c ELISA was used to test the ability of S-FhSAP2 to react with specific anti-FhSAP2, anti-ESP sera or a pool of sera from animals with 4 weeks of F. hepatica infection. d Protein yield and expression protocol duration when FhSAP2 is expressed in E. coli vs. a cell-free expression system. *Includes a primary overnight culture of E. coli that is further used to inoculate 1 l of culture until exponential phase, followed by 4 h of expression induction with 0.02% l-arabinose, and purification of protein from inclusion bodies. **Estimated after purification by BCA method that the protein produced by this approach could be used in immunization experiments and immunodiagnostic techniques.
